The partial depletion of red blood cells via the administration of a low dose of anti-erythrocyte antibodies increases the circulation half-life of nanomedicines, as shown in rodent models of cancer.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$99.00 per year
only $8.25 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nel, A. et al. Nat. Mater. 8, 543–557 (2009).
Cabral, H., Miyata, K., Osada, K. & Kataoka, K. Chem. Rev. 118, 6844–6892 (2018).
Hu, C.-M. J. et al. Nature 526, 118–121 (2015).
Sarett, S. M. et al. Proc. Natl Acad. Sci. USA 114, E6490–E6497 (2017).
Anselmo, A. C. et al. ACS Nano 7, 11129–11137 (2013).
Proffitt, R. et al. Science 220, 502–505 (1983).
Nikitin, M. P. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-020-0581-2 (2020).
Lundqvist, M. et al. Proc. Natl Acad. Sci. USA 105, 14265–14270 (2008).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
K.K. is scientific advisor of NanoCarrier. The remaining author declares no competing interests.
Rights and permissions
About this article
Cite this article
Cabral, H., Kataoka, K. Erythrocyte depletion lifts nanoparticle half-lives. Nat Biomed Eng 4, 670–671 (2020). https://doi.org/10.1038/s41551-020-0586-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-020-0586-x